Robert N. Wilson Buys 8,443 Shares of CalciMedica, Inc. (NASDAQ:CALC) Stock

CalciMedica, Inc. (NASDAQ:CALC) Director Robert N. Wilson purchased 8,443 shares of CalciMedica stock in a transaction on Thursday, June 27th. The stock was bought at an average price of $3.23 per share, for a total transaction of $27,270.89. Following the completion of the acquisition, the director now owns 258,918 shares in the company, valued at approximately $836,305.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

CalciMedica Stock Down 5.6 %

CalciMedica stock opened at $4.01 on Wednesday. The company’s 50-day moving average price is $5.25 and its 200-day moving average price is $4.64. CalciMedica, Inc. has a twelve month low of $1.75 and a twelve month high of $8.38. The company has a market cap of $43.11 million, a PE ratio of -1.87 and a beta of 1.28.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. As a group, sell-side analysts expect that CalciMedica, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of CalciMedica in a report on Thursday, June 27th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price target on shares of CalciMedica in a report on Monday, April 1st. Finally, Singular Research upgraded shares of CalciMedica to a “moderate buy” rating in a report on Friday, June 28th.

Institutional Trading of CalciMedica

A number of large investors have recently made changes to their positions in CALC. Hudson Bay Capital Management LP bought a new stake in shares of CalciMedica in the 3rd quarter worth about $432,000. BML Capital Management LLC grew its holdings in CalciMedica by 63.8% during the 4th quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after purchasing an additional 56,643 shares during the last quarter. Finally, Meritage Portfolio Management grew its holdings in CalciMedica by 360.0% during the 4th quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock valued at $132,000 after purchasing an additional 36,000 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.